(Blogmensgo, January 11, 2012) The French Agency for Research on AIDS and Viral Hepatitis (ANRS) will test in January 2012, among 300 gay and trans HIV-negative gays, a prevention system of HIV / AIDS antiretroviral treatment. Code Name: Ipergay, acronym for "preventive intervention risk exposure with and for gays."
The 300 volunteers who test the "pre-exposure prophylaxis for HIV" (Prep) will swallow two tablets of Truvada before and during the peak of sexual activity, then a third tablet after this period. Half of the cohort swallow a placebo without knowing it.
Designed by the U.S. pharmaceutical company Gilead Sciences, Truvada combines two active ingredients, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). Its use will complement - not replace - the means of prevention and screening routine, which will be offered to participants: condoms, vaccination against hepatitis A and B, screening for infections and sexually transmitted diseases. It is not just a drug prophylaxis, but a combination prevention.
The experiment will take place in Paris, Lyon and Montreal. If it proves successful, a second phase will add 1,600 volunteers in the initial cohort.
A similar experiment was conducted in six countries, 2007-2009 (iPrEx trial, cf. Our article of 24 November 2010). But Ipergay distribute the drugs as requested by voluntary participants, as required by the protocol iPrEx had resulted in deficiencies in the adherence and a reduced risk of contamination of only 44%.
Comment. "Gays are among new HIV-positive, and rarely detected earlier at the AIDS stage," says the ANRS in its press release in PDF. The ANRS forget, however, that gays are historically the people who paid the highest price to the pandemic.
That said, I like this acronym: Ipergay is almost hyperfun.
Philca & Matt/ MensGo